Extended Product Claims for LiquiBand Exceed

Nov 3, 2015

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 3015E
Advanced Medical Solutions Grp PLC
03 November 2015
 

3 November 2015

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

FDA Approves Extended Product Claims for LiquiBand® Exceed™ Topical Skin Adhesive

 

Winsford, UK, 3 November 2015 – Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announced that the FDA has approved two new product claims for the octyl formulation product, LiquiBand Exceed™ giving it a competitive advantage in the topical skin adhesive market. 

 

These claims will allow AMS and partners to differentiate LiquiBand Exceed™ around wound coverage, yield and reuse, providing clinicians with the ability to increase the usage of a single applicator, saving time and cost.

 

The two new claims include the use of a single device to cover wounds of up to 30cm, as well as a single device being suitable for intraoperative reuse for up to 90 minutes on a single patient. Both claims are unique FDA approved claims for the US Topical Skin Adhesive Market. 

 

Following testing, LiquiBand® Exceed™ was found to deliver best in class yield to support coverage up to 30cm of wound length1, twice the amount advertised by market leading topical skin adhesive products2.  Due to the proprietary LiquiBand Exceed™ formula, the adhesive polymerises via skin contact using naturally occurring skin moisture meaning that the applicator device does not dry out.  In-vitro testing proved the device could continually express glue in intervals for up to 90 minutes after device activation.1 

 

Chris Meredith, Chief Executive Officer of AMS, commented: LiquiBand Exceed™ has been an excellent addition to our LiquiBand® topical skin adhesive portfolio demonstrating encouraging initial uptake since its launch this year.  These extended US product claims will help us to continue to provide a superior product for clinicians and a versatile solution for healthcare providers in this key market, in which we are focused on growing our market share.

 

References:

1.   Data on file at Advanced Medical Solutions (Plymouth) Ltd.

2.   www.ethicon.com/healthcare-professionals/products/wound-closure/skin-adhesives/dermabond-advanced-topical-skin-adhesive#!description-and-specs 

 

–     Ends –

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Ivar Milligan


 

About Advanced Medical Solutions Group plc – see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 470 employees.  For more information please see www.admedsol.com.

About LiquiBand® Exceed™

The LiquiBand® portfolio of topical skin adhesives have been developed to provide the global medical market with innovative wound closure products.  The LiquiBand® devices have been uniquely designed to meet the needs of clinicians and patients for safe, secure and effective topical wound closure.

LiquiBand® Exceed™ is the newest and most innovative topical skin adhesive to join the LiquiBand® family of products.  LIQUIBAND Exceed™ is a 2-octyl cyanoacrylate adhesive that has a unique felt applicator tip to facilitate even, consistent application.  The pure octyl formulation maximizes durability and flexibility while providing high viscosity.  LiquiBand® Exceed™ provides an effective microbial barrier to gram positive, gram negative and fungal microbes. The porous felt applicator tip creates even, consistent application while also preventing squirting and dripping of adhesive.  The tip has an elliptical shape to allow for versatility in application technique and can provide wide or narrow application strips.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

NRALFFELLSLFIIE

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.